New prognostic histological parameter of invasive ductal carcinoma of the breast: Clinicopathological significance of fibrotic focus

Pathology International

Volumn 50, Issue 4, 2000, Pages 263-272

  Hasebe, Takahiro ^a   Mukai, Kiyoshi ^a,b   Tsuda, Hitoshi ^a   Ochiai, Atsushi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Breast cancer; Fibrotic focus; Growth factor; Growth factor receptor; Histology; Invasive ductal carcinoma; Prognosis; Proliferative activity; Tumor grade

Indexed keywords

DNA; ESTROGEN RECEPTOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; ONCOPROTEIN; PROTEIN P53;

ANGIOGENESIS; CANCER CLASSIFICATION; CANCER INVASION; CANCER RECURRENCE; CELL PROLIFERATION; FIBROBLAST; FIBROSIS; HISTOPATHOLOGY; HUMAN; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STROMA CELL; TREATMENT OUTCOME;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; FIBROSIS; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 0033947545     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1827.2000.01035.x     Document Type: Review

References (77)

1. 1 Wright C, Angus B, Nicholson S et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989; 49: 2087-2090.
2. 2 Iwaya K, Tsuda H, Hiraide H et al. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn. J. Cancer Res. 1991; 82: 835-840.
3. 3 Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR. Immunohistochemical detection of p53 protein in mammary carcinoma: An important new independent indicator of prognosis? Hum. Pathol. 1993; 24: 469-476.
4. 4 Tahan SR, Neuberg DS, Dieffenbach A, Yacoub L. Prediction of early relapse and shortened survival in patients with breast cancer by proliferating cell nuclear antigen score. Cancer 1993; 71: 3552-3559.
5. 5 Barnes R, Masood S, Barker E et al. Low nm23 protein expression in infiltrating ductal breast carcinomas correlates with reduced patient survival. Am. J. Pathol. 1991; 139: 245-250.
6. 6 Fallenius AG, Auer GU, Carstensen JM. Prognostic significance of DNA measurements in 409 consecutive breast cancer patients. Cancer 1988; 62: 331-341.
7. 7 Cornelisse CJ, van de Velde CJH, Caspers RJC, Moolenaar AJ, Hermans J. DNA ploidy and survival in breast cancer patients. Cytometry 1987; 8: 225-234.
8. 8 Witzig TE, Gonchoroff NJ, Therneau T et al. DNA content flow cytometry as a prognostic factor for node-positive breast cancer. Cancer 1991; 68: 1781-1788.
9. 9 Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
10. 10 Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res. 1991; 51: 944-948.
11. 11 Tsuda H, Hirohashi S, Shimosato Y et al. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res. 1989; 49: 3104-3108.
12. 12 Weidner N, Folkman J, Pozza F et al. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl Cancer Inst. 1992; 84: 1875-1887.
13. 13 Jacquemier JD, Penault-Llorca FM, Bertucci F et al. Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: A multiparametric and immunohistochemical analysis. J. Pathol. 1998; 184: 130-135.
14. 14 Kumar S, Ghellal A, Li C et al. Breast carcinoma: Vascular density determined using CD 105 antibody correlates with tumor prognosis. Cancer Res. 1999; 15: 856-861.
15. 15 Umeda T, Eguchi Y, Okino K, Kodama M, Hattori T. Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues. J. Pathol. 1997; 183: 388-397.
16. 16 Knoop A, Andreasen PA, Andersen JA et al. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br. J. Cancer 1998; 77: 932-940.
17. 17 Ahmad A, Hanby A, Dublin E et al. Stromelysin 3: An independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression. Am. J. Pathol. 1998; 152: 721-728.
18. 18 Cutler SJ, Black MM, Mork T, Harvei S, Freeman C. Further observations on prognostic factors in cancer of the female breast. Cancer 1969; 24: 653-667.
19. 19 Fisher B, Slack NH, Bross IDJ. Cooperating investigators. Cancer of the breast: Size of neoplasm and prognosis. Cancer 1969; 24: 1071-1080.
20. 20 Bloom HJG, Field JR. Impact of tumor grade and host resistance on survival of women with breast cancer. Cancer 1971; 28: 1580-1589.
21. 21 Say CC, Donegan WL. Invasive carcinoma of the breast. Prognostic significance of tumor size and involved axillary lymph nodes. Cancer 1974; 34: 468-471.
22. 22 Fisher ER, Palekar A, Rockette H, Redmond CK, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol no. 4) - V. Significance of axillary nodal micro-and macrometastases. Cancer 1978; 42: 2032-2038.
23. 23 Fisher B, Bauer M, Wickerham L, Redmond CK, Fisher ER. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. Cancer 1983; 52: 1551-1557.
24. 24 Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24 740 breast cancer cases. Cancer 1989; 63: 181-187.
25. 25 Wolman SR, Feiner HD, Schinella RA et al. A retrospective analysis of breast cancer based on outcome differences. Hum. Pathol. 1991; 22: 475-480.
26. 26 Gilchrist KW, Gray R, Fowble B, Tormey DC, Taylor IV. Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer: A 10-year follow-up study of 728 Eastern Cooperative Oncology Group patients. J. Clin. Oncol. 1993; 11: 1929-1935.
27. 27 Younes M, Laucirica R. Lack of prognostic significance of histological grade in node-negative invasive breast carcinoma. Clin. Cancer Res. 1997; 3: 601-604.
28. 28 Albert R, Muller JG, Kristen P, Harms H. Objective nuclear grading for node-negative breast cancer patients: comparison of quasi-3D and 2D image-analysis based on light microscopic images. Lab. Invest. 1998; 78: 247-259.
29. 29 Lampe B, Hantschmann P, Dimpfl T. Prognostic relevance of immunohistology, tumor size and vascular space involvement in axillary node negative breast cancer. Arch. Gyn. Obst. 1998; 261: 139-146.
30. 30 Saiz E, Toonkei R, Poppiti RJ, Robinson MJ. Infiltrating breast carcinoma smaller than 0.5 cm. Is lymph node dissection necessary? Cancer 1999; 85: 2206-2211.
31. 31 Chen YY, Schnitt SJ. Prognostic factors for patients with breast cancer 1 cm and smaller. Breast Cancer Res. Treat. 1998; 51: 209-225.
32. 32 Barth A, Craig PH, Silverstein MJ. Predictors of axillary lymph node metastasis in patients with T1 breast carcinoma. Cancer 1997; 79: 1918-1922.
33. 33 Lauria R, Perrone F, Carlomagno C et al. The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. Cancer 1995; 76: 1772-1778.
34. 34 Joshi MG, Lee AKC, Loda M et al. Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer 1996; 77: 490-498.
35. 35 Linell F, Ljungberg O, Andersson I. Breast carcinoma. Aspects of early stages, progression, and related problems. Acta Pathol. Microbiol. Scand. 1980; (Suppl. 272): 1-233.
36. 36 Fisher ER, Palekar AS, Sass R, Fisher B. Scar cancers: pathologic findings from the National Surgical Adjuvant Breast Project (protocol no. 4) - IX. Breast Cancer Res. Treat. 1983; 3: 39-59.
37. 37 Toikkanen S, Joensuu H. Long-term prognosis of scar and non-scar cancers of the breast. APMIS 1990; 98: 1033-1038.
38. 38 Partanen S, Hyvarinen H. Scar and non-scar ductal cancer of the female breast. Observations on patient age, tumour size, and hormone receptors. Virchows Arch (A) Pathol. Anat. 1987; 412: 145-149.
39. 39 Hasebe T, Tsuda H, Hirohashi S et al. Fibrotic focus in invasive ductal carcinoma: an indicator of high tumor aggressiveness. Jpn. J. Cancer Res. 1996; 87: 385-394.
40. 40 Hasebe T, Tsuda H, Tsubono Y, Imoto S, Mukai K. Fibrotic focus in invasive ductal carcinoma: a histopathological prognostic parameter for tumor recurrence and tumor death within three years after the initial operation. Jpn. J. Cancer Res. 1997; 88: 590-599.
41. 41 Hasebe T, Tsuda H, Hirohashi S et al. Fibrotic focus in infiltrating ductal carcinoma of the breast: a significant histopathological prognostic parameter for predicting the long-term survival of the patients. Breast Cancer Res. Treat. 1998; 49: 195-208.
42. 42 Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
43. 43 Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53: 457-481.
44. 44 Cox DR. Regression models and life-tables. J. R. Stat. Soc. 1972; 34: 187-220.
45. 45 Koyama T, Hasebe T, Tsuda H et al. Histological factors associated with initial bone metastasis of invasive ductal carcinoma of the breast. Jpn. J. Cancer Res. 1999; 90: 294-300.
46. 46 Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma. Cancer 1950; 3: 74-85.
47. 47 Jitsuiki Y, Hasebe T, Tsuda H et al. Optimizing microvessel counts according to tumor zone in invasive ductal carcinoma of the breast. Mod. Pathol. 1999; 12: 492-498.
48. 48 Silvestrini R, Benini E, Daidone MG et al. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J. Natl Cancer Inst. 1993; 85: 965-971.
49. 49 Aaltomaa S, Lipponen P, Papinaho S, Syrjanen K. Proliferating-cell nuclear antigen (PC10) immunolabelling and other proliferation indices as prognostic factors in breast cancer. J. Cancer Res. Clin. Oncol. 1993; 119: 288-294.
50. 50 Auer G, Eriksson E, Azavedo E, Caspersson T, Wallgren A. Prognostic significance of nuclear DNA content in mammary adenocarcinomas in humans. Cancer Res. 1984; 44: 394-396.
51. 51 Hedley DW, Friedlander ML, Taylor IW. Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance. Cytometry 1985; 6: 327-333.
52. 52 Peiro G, Lerma E, Climent MA, Segui MA, Alonso MC, Prat J. Prognostic value of s-phase fraction in lymph-node-negative breast cancer by image and flow cytometric analysis. Mod. Pathol. 1997; 10: 216-222.
53. 53 Rifkin DB, Moscatelli D. Recent developments in the cell biology of basic fibroblast growth factor. J. Cell Biol. 1989; 109: 1-6.
54. 54 Gospodarowicz D. The fibroblast growth factor. Oncogenesis 1989; 1: 1-25.
55. 55 Souttou B, Hamelin R, Crepin M. FGF2 as an autocrine growth factor for immortal human breast epithelial cells. Cell Growth Differen. 1994; 5: 615-623.
56. 56 Luamani YA, Graham M, Coombes RC. Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant breast, and comparison with other normal tissues. Br. J. Cancer 1992; 66: 273-280.
57. 57 Jonson DE, Williams LT. Structural and functional diversity in the FGF receptor multigene family. Adv. Cancer Res. 1993; 60: 1-41.
58. 58 Jacquemier J, Adelaide J, Parc P et al. Expression of the FGFR1 gene in human breast carcinoma cells. Int. J. Cancer 1994; 59: 373-378.
59. 59 Rosenbaum J, Blazejewski S, Anne-Marie P, Mallat A, Dhumeaux D, Mavier P. Fibroblast growth factor 2 and transforming growth factor β1 interactions in human liver myofibroblasts. Gastroenterology 1995; 109: 1986-1996.
60. 60 Wilson SE, Lioyd SA, He YG. Fibroblast growth factor-1 receptor messenger RNA expression in corneal cells. Cornea 1993; 12: 249-254.
61. 61 Hasebe T, Imoto S, Ogura T, Mukai K. Significance of basic fibroblast growth factor and fibroblast growth factor receptor protein expression in the formation of fibrotic focus in invasive ductal carcinoma of the breast. Jpn. J. Cancer Res. 1997; 88: 877-885.
62. 62 Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br. J. Cancer 1957; 11: 359-377.
63. 63 Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 1989; 64: 1914-1921.
64. 64 Todd JH, Dowle C, Williams MR et al. Confirmation of a prognostic index in primary breast cancer. Br. J. Cancer 1987; 56: 489-492.
65. 65 Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham prognostic index in primary breast cancer. Breast Cancer Res. Treat. 1992; 22: 207-219.
66. 66 Hasebe T, Imoto S, Sasaki S, Mukai K. A proposal for a new histological classification scheme for predicting short-term tumor recurrence and death in patients with invasive ductal carcinoma of the breast. Jpn. J. Cancer Res. 1998; 89: 1358-1373.
67. 67 Hasebe T, Sasaki S, Imoto S, Ochiai A. Proliferative activity of intratumoral fibroblasts is closely correlated with lymph node and distant organ metastasis of invasive ductal carcinoma of the breast. Am. J. Pathol. 2000; (in press).
68. 68 von Marshall Z, Riecken EO, Rosewicz S. Stromelysin 3 is overexpressed in human pancreatic carcinoma and regulated by retionic acid in pancreatic carcinoma cell lines. Gut 1998; 34: 692-698.
69. 69 Okusa Y, Ichikura T, Mochizuki H. Prognostic impact of stromal cell-derived urokinase-type plasminogen activator in gastric carcinoma. Cancer 1998; 85: 1033-1038.
70. 70 Boyd RS, Balkwill FR. MMP-2 release and activation in ovarian carcinoma: the role of fibroblasts. Br. J. Cancer 1999; 80: 315-321.
71. 71 Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998; 58: 2825-2831.
72. 72 Krsch M, Strasser J, Allende R, Bello L, Zhang J, Black PM. Angiostatin suppress malignant glioma growth in vivo. Cancer Res. 1998; 58: 4654-4659.
73. 73 Parmigiani G, Berry DA, Winer EP et al. Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis. J. Clin. Oncol. 1999; 17: 1465-1473.
74. 74 Reynolds C, Mick R, Donohue JH et al. Sentinel lymph node biopsy with metastasis: Can axillary dissection be avoided in some patients with breast cancer? J. Clin. Oncol. 1999; 17: 1720-1726.
75. 75 Imoto S, Hasebe T. Initial experience with sentinel node biopsy in breast cancer at the National Cancer Center Hospital East. Jpn. J. Clin. Oncol. 1999; 29: 11-15.
76. 76 Diab SG, Clark GM, Kent Osborne C et al. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J. Clin. Oncol. 1999; 17: 1442-1448.
77. 77 Casey M, Rosenblatt R, Zimmerman J, Fineberg S. Mastectomy without malignancy after carcinoma diagnosed by large core stereotactic breast biopsy. Mod. Pathol. 1997; 10: 1209-1213.